BCG vs. Chemohyperthermia: Which Bladder Cancer Treatment is Right for You?
"A new study compares the effectiveness of BCG and chemohyperthermia for high-risk non-muscle-invasive bladder cancer. Find out which treatment shows more promise."
Bladder cancer is a major health concern, ranking as the fourth most common cancer among American men. The good news is that if caught early, when the cancer is non-muscle-invasive (NMIBC), the five-year survival rate is high. However, even with successful initial treatment, many patients face a risk of recurrence, making ongoing care essential.
After the initial tumor removal, patients with high-risk NMIBC often need additional treatments, called adjuvant therapies, to prevent the cancer from returning or progressing. Bacillus Calmette-Guérin (BCG), a type of immunotherapy, has long been a primary choice. However, because BCG can have significant side effects, researchers continue to explore new and improved options.
One such alternative is chemohyperthermia (C-HT), which combines chemotherapy with heat to target cancer cells. While several studies have suggested that C-HT could be beneficial, direct comparisons between BCG and C-HT have been lacking. Now, a new study sheds light on how these two treatments stack up against each other.
Bladder Cancer: A Growing Burden
Non-muscle-invasive bladder cancer (NMIBC) represents the majority of bladder cancer cases at diagnosis, and its management places a significant burden on healthcare systems. Overall five-year survival for bladder cancer stands at approximately 77.9%, though outcomes vary considerably by stage and treatment adherence. Real-world data from German health claims and European multicenter databases reveal that many patients do not receive adequate BCG treatment as defined by international guidelines, highlighting a persistent gap between evidence-based standards and actual clinical practice.
BCG: The Gold Standard with Known Shortcomings
Intravesical Bacillus Calmette-Guérin (BCG) has been the standard adjuvant immunotherapy for non-muscle-invasive bladder cancer for over three decades. Despite its proven efficacy, BCG therapy faces significant challenges: resistance develops in 30%–50% of patients, and the standard 80 mg dose is frequently associated with significant adverse events. Standard-dose BCG carries a notable toxicity burden, prompting research into tailored lower doses (such as 40 mg) that may maintain efficacy while reducing side effects.
A Treatment with Deep Roots
The use of BCG in bladder cancer traces back to its origins as a tuberculosis vaccine, eventually repurposed for oncological applications through decades of clinical investigation. Over the years, BCG became firmly established as the gold standard adjuvant therapy for high-risk NMIBC after demonstrated superiority over alternatives. More recently, ongoing research has sought to refine BCG delivery, optimize dosing schedules, and better understand its immune-mediated mechanisms of action.
The Study: Comparing BCG and Chemohyperthermia
Researchers conducted a retrospective study to compare the effectiveness of BCG and C-HT in patients with high-risk NMIBC. The study included 1937 patients diagnosed with bladder cancer between January 2004 and January 2014. Of these, 710 patients received intravesical treatments (directly into the bladder), with some receiving C-HT and others receiving BCG.
- Patient Selection: The study focused on patients with high-risk NMIBC who underwent transurethral resection (TUR), a procedure to remove bladder tumors.
- Treatment Groups: Patients were treated with either intravesical C-HT or BCG instillation. The C-HT involved using a special unit to heat the bladder wall while administering chemotherapy. BCG was given weekly for six weeks.
- Follow-up: Patients underwent regular cystoscopies (bladder exams) and urine tests to monitor for recurrence.
- Statistical Analysis: The researchers used statistical methods to compare the recurrence-free intervals between the two treatment groups and to identify factors associated with recurrence and progression.
New Frontiers in Bladder Cancer Immunotherapy
Recent systematic reviews and meta-analyses have evaluated novel intravesical and systemic combination therapies for BCG-naïve NMIBC patients, including combinations with immune-checkpoint inhibitors (ICIs). Literature reviews published in 2025 emphasize the mechanisms of BCG immune-mediated anti-cancer activity alongside emerging resistance pathways, providing updated frameworks for understanding treatment response. Parallel advances in vaccine-based therapies and genetically engineered oncolytic bacteria are also gaining attention as potential complements or alternatives to traditional BCG approaches.
When BCG Falls Short
A substantial proportion of patients—estimates range from 30% to 40%—fail to respond to BCG treatment, experiencing either primary resistance or disease relapse after initial response. BCG failure is clinically classified into three categories: BCG-refractory, relapsing, and intolerant disease, each carrying distinct prognostic and treatment implications. Notably, there is currently no universally agreed-upon gold standard for salvage treatment following BCG failure, nor is there a single unified definition of what constitutes BCG failure across guidelines.
BCG Against Alternatives
Comprehensive reviews published in 2024 revisit both the historical role of BCG and its alternative therapies, including novel therapeutics approved for BCG-unresponsive disease and those under active investigation. BCG shortages in some regions have accelerated the adoption of sequential intravesical gemcitabine and docetaxel (Gem/Doce) as a promising alternative regimen for intermediate- and high-risk NMIBC. However, comparative data on treatment burden and resource utilization between BCG and these alternative regimens remain limited, with ongoing studies seeking to clarify the relative merits of each approach.
The Bottom Line: BCG Remains the Gold Standard, For Now
This study suggests that for patients with high-risk NMIBC who have not previously received BCG, BCG remains the more effective treatment option. While chemohyperthermia may offer an alternative for some patients, it did not perform as well as BCG in preventing cancer recurrence. However, it’s important to remember that this was a retrospective study, and more research is needed to confirm these findings. Future studies should also explore ways to improve chemohyperthermia or identify specific patients who might benefit most from this approach. If you have high-risk NMIBC, talk to your doctor about the best treatment plan for you.
Where the Evidence Points
The current evidence base underscores that BCG remains the foundational treatment for high-risk NMIBC, yet significant gaps persist in optimizing its delivery and managing patients who fail therapy. Experts broadly agree that individualized treatment strategies—accounting for disease risk, prior treatment history, and patient tolerance—are essential for improving outcomes. As novel therapies and combination approaches mature, the field appears to be moving toward a more nuanced, multi-modal paradigm rather than a single standard-of-care solution.
Testing New Standards in 2025 and Beyond
The integration of immune-checkpoint inhibitors into earlier stages of urothelial cancer has long been anticipated, and 2025 marks a pivotal moment with the publication of the POTOMAC and CREST trials in BCG-naïve high-risk NMIBC. These landmark studies represent the first major tests of combining ICIs with intravesical therapy in the non-muscle-invasive setting, potentially reshaping treatment algorithms. If positive, these results could expand systemic immunotherapy options well beyond their current use in advanced or metastatic disease.
Systemic Barriers to Effective Treatment
Despite BCG's established role as the first-line treatment for NMIBC, its widespread use is undermined by limitations including systemic toxicity, BCG unresponsiveness in a significant minority of patients, and rapid bladder clearance that may compromise drug efficacy. These challenges have driven the search for novel therapeutic strategies that can overcome resistance and reduce the burden on patients. The field increasingly recognizes that addressing these systemic barriers requires not just new drugs, but also improvements in treatment scheduling, dosing optimization, and patient selection.
Outcomes in Everyday Practice
Contemporary real-world data from the United States reveal that many patients with high-risk NMIBC receive BCG treatment inadequately or not at all, pointing to significant gaps between guideline recommendations and routine clinical practice. Studies from global clinical practice have identified factors contributing to inadequate BCG delivery, including patient comorbidities, provider experience, and systemic resource constraints. Case studies documenting BCG's repurposing from tuberculosis prevention to bladder cancer therapy further highlight both the versatility of this approach and the practical challenges patients face in accessing it consistently.